HSRx Biopharmaceutical, presumably under license from HerbalScience Group, is developing HSRx 431, a combination of berry-derived food nutrients and a generic drug, for the treatment of Zika virus infection, dengue and chikungunya virus infection. The disease-fighting food nutrients are integrated with the generic drug to create an orally delivered polyfunctional pharmaceutical product. HSRx utilizes BRILLIANT™, a technology platform developed by HerbalScience, to create its proprietary food nutrients. The food nutrients attaches to Zika virus, and prevents the virus from entering host cells. Phase I development is underway for Zika virus infection and chikungunya virus infection, and preclinical development is underway for dengue.
As at January 2020, no recent reports of development had been identified for phase-I development in Chikungunya-virus-infections in Unknown (PO), phase-I development in Zika-virus-infection in Unknown (PO).
As at October 2020, no recent reports of development had been identified for preclinical development in Dengue in USA (PO).
In August 2015, HSRx acquired a portfolio of 10 proprietary OTC drug products and in-licensed 8 proprietary disease-specific pharmaceutical products from HerbalScience Group  .
Key Development Milestones
Phase I development is underway to evaluate the safety of HSRx 431 against Zika virus and chikungunya virus infections (HSRx Biopharmaceutical pipeline, December 2016).
HSRx Biopharmaceutical planned to seek for accelerated drug approval from the US FDA  .
Screening studies of HSRx 431 confirmed its effectiveness against Zika virus. Earlier, in vivo studies demonstrated the safety and effectiveness of the drug against dengue and chikungunya infections  .
HSRx Biopharmaceutical has patented HSRx 431 alone and in combination with oseltamivir (Tamiflu™) and other anti-virals  .